Roche is increasing its presence in the diagnostics sector by acquiring GenMark Diagnostics for $1.8 billion, the Swiss drugmaker announced March 15.
Carlsbad, Calif.-based GenMark produces molecular tests that can identify the presence of several different pathogens, including those that cause COVID-19, from a single sample.
Roche will pay $24.05 per share in an all-cash transaction. The deal is expected to close in 2021's second quarter.
More articles on pharmacy:
HHS allows retired pharmacists, pharmacy interns to give COVID-19 vaccinations
Sanofi launches trial for 2nd COVID-19 vaccine candidate
Gilead, Merck co-developing long-acting HIV treatment